Filter
Period
Filter by
recent search
Showing: 1 – 05 of 20 Corporate News
–
11 July 2024
11 July 2024
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential
PARIS, FRANCE, 11 July 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) and Foreseen Biotechnology (Foreseen) today announced an exclusive global licensing agreement for FS001, an antibody-drug conjugate (ADC) with first-in-class potential. FS001 targets a novel tumor-associated antigen that is overexpressed…
–
22 April 2024
22 April 2024
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
PARIS, FRANCE; BOSTON, U.S., 22 April 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) and Skyhawk Therapeutics today announced the signing of an exclusive worldwide collaboration to discover and develop novel small molecules that modulate RNA for rare neurological diseases. The…
–
02 April 2024
02 April 2024
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
PARIS, FRANCE; SAN FRANCISCO, U.S., 02 April 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) and Sutro Biopharma (NASDAQ: STRO, “Sutro”, “the Company”) today announced an exclusive global licensing agreement for STRO-003. STRO-003, an antibody-drug conjugate (ADC) in the final stages…
–
07 December 2023
07 December 2023
Capital Markets Day 2023 – Ipsen outlines next phase of growth & transformation and provides new mid-term outlook
PARIS, FRANCE, 7 December 2023 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, today holds its Capital Markets Day in London, U.K.
Your dedicated contacts
-
Craig Marks
Vice President, Investor Relations
-
-
Nicolas Bogler
Senior Manager, Investor Relations
-